Physician profile
Christopher D Caffrey
NPI 1710287578
$7,114.01
in general payments reported to CMS, 2019-2025
41 companies · $2,120 in 2025
The $2,120 reported for 2025 was more than what 97% of Psychiatric/Mental Health, Child & Family providers received nationally (typical 2025 total: $178).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $396 · 2022: $1,588 · 2023: $1,385 · 2024: $1,624 · 2025: $2,120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,129.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,216.79 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,182.78 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Pfizer INC. | $482.29 | 2023-2025 | |
| Madrigal Pharmaceuticals | $340.83 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $317.69 | 2022-2025 | |
| Janssen Biotech, INC. | $233.60 | 2022-2025 | Simponi, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $219.03 | 2021-2025 | Trintellix, Entyvio |
| Regeneron Healthcare Solutions, INC. | $178.57 | 2022-2025 | Dupixent |
| Celgene Corporation | $177.69 | 2021-2023 | Zeposia |
| Ironwood Pharmaceuticals, INC | $132.36 | 2022-2025 | Linzess |
| Ferring Pharmaceuticals INC. | $131.64 | 2022-2023 | Cimzia, Clenpiq |
| Intercept Pharmaceuticals, INC. | $121.04 | 2021-2025 | Ocaliva |
| Gilead Sciences, INC. | $107.85 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $106.62 | 2023-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $100.01 | 2022-2025 | Cobenfy |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Caffrey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.